MarginEdge Recognized by Inc.’s Power Partner Awards and Washington Business Journal’s Fastest Growing Companies 2023
October 24, 2023 08:00 ET
|
MarginEdge
ARLINGTON, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- MarginEdge, the leading restaurant management and bill payment platform, today announced it has been recognized by the 2023 Inc. Power Partners...
Text Request Honored with Inc. Power Partner Award for 2nd Year
October 24, 2023 07:33 ET
|
Text Request
CHATTANOOGA, TENN., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Text Request, the industry-leading business messaging platform, has been recognized as an Inc. Power Partner for the second year in a row....
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)
October 03, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
- Top-line Data Anticipated Around Year End WAYNE, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 20, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor
September 18, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
– Preliminary Data Support Progression to Phase 2a Proof of Concept Trials in T cell-mediated Autoimmune Diseases – WAYNE, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc....
Psoriatic Arthritis Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - Bristol-Myers Squibb, Aclaris, AbbVie, Novartis, Janssen, MoonLake, Affibody, Amgen, Eli Lilly
August 31, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Psoriatic Arthritis Market to Register Immense Growth by 2032, Assesses DelveInsight | Key Companies to Look Out - Bristol-Myers Squibb, Aclaris,...
Barrack, Rodos & Bacine Investigates Napco Security Technologies, Inc. (NSSC)
August 24, 2023 09:30 ET
|
Barrack Rodos & Bacine
PHILADELPHIA, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Barrack, Rodos & Bacine (BR&B) is investigating Napco Security Technologies, Inc. (“Napco”) (NASDAQ: NSSC) for potential violations of federal...
Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update
August 07, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
- Completion of Enrollment in Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis As Previously Announced; Data Expected in Q4 2023 - WAYNE, Pa., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Aclaris...
Psoriasis Market to Register Immense Growth by 2032, Predicts DelveInsight | Key Companies Working in Space - Biohaven, Bristol-Myers Squibb, UCB Pharma, Janssen, Novartis, Pfizer, Boehringer Ingelheim, AbbVie, Aclaris
July 25, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, July 25, 2023 (GLOBE NEWSWIRE) -- Psoriasis Market to Register Immense Growth by 2032, Predicts DelveInsight | Key Companies Working in Space - Biohaven, Bristol-Myers Squibb, UCB...
Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)
June 13, 2023 07:01 ET
|
Aclaris Therapeutics, Inc.
- Topline Data Anticipated in Q4 2023 WAYNE, Pa., June 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...